Last reviewed · How we verify
Empagliflozin Oral Tablet [Jardiance]
Empagliflozin Oral Tablet [Jardiance] is a Small molecule drug developed by Royal Perth Hospital. It is currently FDA-approved.
At a glance
| Generic name | Empagliflozin Oral Tablet [Jardiance] |
|---|---|
| Sponsor | Royal Perth Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Empagliflozin Oral Tablet [Jardiance] CI brief — competitive landscape report
- Empagliflozin Oral Tablet [Jardiance] updates RSS · CI watch RSS
- Royal Perth Hospital portfolio CI
Frequently asked questions about Empagliflozin Oral Tablet [Jardiance]
What is Empagliflozin Oral Tablet [Jardiance]?
Empagliflozin Oral Tablet [Jardiance] is a Small molecule drug developed by Royal Perth Hospital.
Who makes Empagliflozin Oral Tablet [Jardiance]?
Empagliflozin Oral Tablet [Jardiance] is developed and marketed by Royal Perth Hospital (see full Royal Perth Hospital pipeline at /company/royal-perth-hospital).
What development phase is Empagliflozin Oral Tablet [Jardiance] in?
Empagliflozin Oral Tablet [Jardiance] is FDA-approved (marketed).